Microwave-controlled generation of shaped single photons in circuit quantum electrodynamics

Large-scale quantum information processors or quantum communication networks will require reliable exchange of information between spatially separated nodes. The links connecting these nodes can be established using traveling photons that need to be absorbed at the receiving node with high efficiency. This is achievable by shaping the temporal profile of the photons and absorbing them at the receiver by time reversing the emission process. Here, we demonstrate a scheme for creating shaped microwave photons using a superconducting transmon-type three-level system coupled to a transmission line resonator. In a second-order process induced by a modulated microwave drive, we controllably transfer a single excitation from the third level of the transmon to the resonator and shape the emitted photon. We reconstruct the density matrices of the created single-photon states and show that the photons are antibunched. We also create multipeaked photons with a controlled amplitude and phase. In contrast to similar existing schemes, the one we present here is based solely on microwave drives, enabling operation with fixed frequency transmons

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Background: Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide is approved in the US and EU for the treatment of type 2 diabetes (T2D) and obesity. In the SURPASS clinical trial program for T2D, tirzepatide demonstrated greater improvements in glycemic control, body weight reduction and other cardiometabolic risk factors versus placebo, subcutaneous semaglutide 1 mg, insulin degludec, and insulin glargine. This post hoc analysis assessed the effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome across SURPASS 1–5. Methods: Metabolic syndrome was defined as having ≥ 3 of 5 criteria according to the US National Cholesterol Education Program: Adult Treatment Panel III. Analyses were based on on-treatment data at the primary endpoint from patients adherent to treatment (taking ≥ 75% study drug). A logistic regression model with metabolic syndrome status as the response variable, metabolic syndrome status at the baseline visit as an adjustment, and randomized treatment as fixed explanatory effect was used. The effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome by categorical weight loss, background medication and gender were assessed. Results: In SURPASS, the prevalence of patients meeting the criteria for metabolic syndrome at baseline was 67–88% across treatment groups with reductions at the primary endpoint to 38–64% with tirzepatide versus 64–82% with comparators. Reductions in the prevalence of patients meeting the criteria for metabolic syndrome was significantly greater with all tirzepatide doses versus placebo, semaglutide 1 mg, insulin glargine, and insulin degludec (p < 0.001). Individual components of metabolic syndrome were also reduced to a greater extent with tirzepatide vs comparators. Greater reductions in body weight were associated with greater reductions in the prevalence of patients meeting the criteria for metabolic syndrome and its individual components. Background SGLT2i or sulfonylurea use or gender did not impact the change in prevalence of patients meeting the criteria for metabolic syndrome. Conclusions: In this post hoc analysis, tirzepatide at all doses studied was associated with a greater reduction in the prevalence of patients meeting the criteria for metabolic syndrome compared to placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. Although more evidence is needed, these data would support greater potential improvement in cardiovascular risk factor profile with tirzepatide treatment in people across the continuum of T2D

Negotiating networks of self-employed work: strategies of minority ethnic contractors

Within the increased flexible, contracted work in cities, employment is negotiated through network arrangements characterised by multiplicity, mobility and fluidity. For black and minority ethnic group members, this network labour becomes fraught as they negotiate both their own communities, which can be complex systems of conflicting networks, as well as non-BME networks which can be exclusionary. This discussion explores the networking experiences of BME individuals who are self-employed in portfolio work arrangements in Canada. The analysis draws from a theoretical frame of ‘racialisation’ (Mirchandani and Chan, 2007) to examine the social processes of continually constructing and positioning the Other as well as the self through representations in these networks. These positions and concomitant identities enroll BME workers in particular modes of social production, which order their roles and movement in the changing dynamics of material production in networked employment

Structural brain correlates of childhood inhibited temperament: an ENIGMA-Anxiety Mega-analysis

NWORubicon 019.201SG.022Pathways through Adolescenc

Weekly cases of selected notifiable diseases ( 65 1,000 cases reported during the preceding year), and selected low frequency diseases, United States and U.S. territories, week ending December 15, 2018 (WEEK 50). TABLE 2o, Salmonellosis (excluding typhoid fever and paratyphoid fever); Shiga toxin-producing Escherichia coli; Shigellosis

2018-50-table2O-H.pdfSalmonellosis (excluding typhoid fever and paratyphoid fever)-- Shiga toxin-producing Escherichia coli --Shigellosis.2018739